Replies to post #53517 on Anavex Life Sciences Corp (AVXL)

[Mikesc]

We got it! Give it a rest..we know what you are saying!!!!

[twiz0019]

Are you serious frrol? First of all, it is YOU, not the market questioning whether another extension was granted. Secondly, if the test results were not good, why are they going to a larger Phase 2/3 trial????

[Miss Australia]

and I think I answered that? My belief from what I have been told, is yes, they did and yes it has. But I don't think that was asked by the market, I think the market will be more interested in results than if the participants asked for yet another extension?

As I also said, this question was asked by most participants at the start of the trial (wouldn't you?), and was answered. So we haven't felt the need to ask again at this stage.

If the next stage of the trial is here, it is always possible it may be approved here before in the USA?

[circa1762]

I fault that logic very much. Cannot assume silence means yes or no -- it means silence. Plus every scientific report so far suggests the drug is working, and working very well. Deducing that has changed because of silence is not logical. That is jumping to an unfounded conclusion.

[JB3729]

We were given preliminary data for the first 12 weeks of PART B in November. The data looks damn good to me -

In the interim analysis of the first 14 patients at week 12, the PART B portion of the study demonstrated a positive trend towards improvement over 12 weeks of ANAVEX 2-73 treatment on the secondary functional outcome measure, the Alzheimer’s Disease Co-operative Study – Activities of Daily Living Inventory (ADCS-ADL) by +3.21 points.
http://www.anavex.com/?news=anavex-announces-positive-primary-and-secondary-endpoints-were-achieved-in-a-phase-2a-clinical-trial-of-anavex-2-73-in-alzheimers-disease%e2%80%8e


Furthermore, this positive dose response data is huge -

NEW YORK, NY – January 11, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported a positive dose-response relationship has been observed in a pre-planned interim analysis of data from the ongoing Phase 2a trial of ANAVEX 2-73 for treatment of mild to moderate Alzheimer’s disease.
http://www.anavex.com/?news=anavex-announces-positive-dose-response-data-for-anavex-2-73-in-alzheimers-disease-patients

It makes no sense to be negative regarding upcoming data at this time!